Immunotherapy is a type of cancer treatment that stimulates a patient’s immune system to attack tumours.
While promising, its effectiveness varies among patients.
The new VUB technology helps identify in advance which patients are likely to benefit from this treatment.
The study introduces an innovative tracer targeting CD163, a molecular receptor on tumour-associated macrophages—immune cells that support tumour growth and protection.
Leave a reply